125 related articles for article (PubMed ID: 23302632)
1. Application of curcumin to heart failure therapy by targeting transcriptional pathway in cardiomyocytes.
Katanasaka Y; Sunagawa Y; Hasegawa K; Morimoto T
Biol Pharm Bull; 2013; 36(1):13-7. PubMed ID: 23302632
[TBL] [Abstract][Full Text] [Related]
2. Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin.
Morimoto T; Sunagawa Y; Fujita M; Hasegawa K
Circ J; 2010 Jun; 74(6):1059-66. PubMed ID: 20467147
[TBL] [Abstract][Full Text] [Related]
3. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats.
Morimoto T; Sunagawa Y; Kawamura T; Takaya T; Wada H; Nagasawa A; Komeda M; Fujita M; Shimatsu A; Kita T; Hasegawa K
J Clin Invest; 2008 Mar; 118(3):868-78. PubMed ID: 18292809
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4.
Suzuki H; Katanasaka Y; Sunagawa Y; Miyazaki Y; Funamoto M; Wada H; Hasegawa K; Morimoto T
Biochim Biophys Acta; 2016 Sep; 1862(9):1544-57. PubMed ID: 27208796
[TBL] [Abstract][Full Text] [Related]
5. [Development of Targeted Pharmacotherapy for Cardiovascular Disease].
Katanasaka Y
Yakugaku Zasshi; 2017; 137(11):1349-1353. PubMed ID: 29093370
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Cardiac Transcription Factor GATA4 by Post-Translational Modification in Cardiomyocyte Hypertrophy and Heart Failure.
Katanasaka Y; Suzuki H; Sunagawa Y; Hasegawa K; Morimoto T
Int Heart J; 2016 Dec; 57(6):672-675. PubMed ID: 27818483
[TBL] [Abstract][Full Text] [Related]
7. [Functional Analysis of GATA4 Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics Approach].
Sunagawa Y; Katanasaka Y; Wada H; Hasegawa K; Morimoto T
Yakugaku Zasshi; 2016; 136(2):151-6. PubMed ID: 26831785
[TBL] [Abstract][Full Text] [Related]
8. Curcumin prevents and reverses murine cardiac hypertrophy.
Li HL; Liu C; de Couto G; Ouzounian M; Sun M; Wang AB; Huang Y; He CW; Shi Y; Chen X; Nghiem MP; Liu Y; Chen M; Dawood F; Fukuoka M; Maekawa Y; Zhang L; Leask A; Ghosh AK; Kirshenbaum LA; Liu PP
J Clin Invest; 2008 Mar; 118(3):879-93. PubMed ID: 18292803
[TBL] [Abstract][Full Text] [Related]
9. Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes.
Takaya T; Kawamura T; Morimoto T; Ono K; Kita T; Shimatsu A; Hasegawa K
J Biol Chem; 2008 Apr; 283(15):9828-35. PubMed ID: 18252717
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes.
Sunagawa Y; Morimoto T; Takaya T; Kaichi S; Wada H; Kawamura T; Fujita M; Shimatsu A; Kita T; Hasegawa K
J Biol Chem; 2010 Mar; 285(13):9556-9568. PubMed ID: 20081228
[TBL] [Abstract][Full Text] [Related]
11. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.
Moey M; Gan XT; Huang CX; Rajapurohitam V; MartÃnez-Abundis E; Lui EM; Karmazyn M
Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957
[TBL] [Abstract][Full Text] [Related]
12. Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response.
Shimizu S; Sunagawa Y; Hajika N; Yorimitsu N; Katanasaka Y; Funamoto M; Miyazaki Y; Sari N; Shimizu K; Hasegawa K; Morimoto T
Int J Biol Sci; 2022; 18(3):1079-1095. PubMed ID: 35173540
[TBL] [Abstract][Full Text] [Related]
13. The Synthetic Curcumin Analogue GO-Y030 Effectively Suppresses the Development of Pressure Overload-induced Heart Failure in Mice.
Shimizu K; Sunagawa Y; Funamoto M; Wakabayashi H; Genpei M; Miyazaki Y; Katanasaka Y; Sari N; Shimizu S; Katayama A; Shibata H; Iwabuchi Y; Kakeya H; Wada H; Hasegawa K; Morimoto T
Sci Rep; 2020 Apr; 10(1):7172. PubMed ID: 32346115
[TBL] [Abstract][Full Text] [Related]
14. Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes.
Sunagawa Y; Funamoto M; Sono S; Shimizu K; Shimizu S; Genpei M; Miyazaki Y; Katanasaka Y; Morimoto E; Ueno M; Komiyama M; Kakeya H; Wada H; Hasegawa K; Morimoto T
J Pharmacol Sci; 2018 Apr; 136(4):212-217. PubMed ID: 29602708
[TBL] [Abstract][Full Text] [Related]
15. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
16. Improved bioavailability of targeted Curcumin delivery efficiently regressed cardiac hypertrophy by modulating apoptotic load within cardiac microenvironment.
Ray A; Rana S; Banerjee D; Mitra A; Datta R; Naskar S; Sarkar S
Toxicol Appl Pharmacol; 2016 Jan; 290():54-65. PubMed ID: 26612707
[TBL] [Abstract][Full Text] [Related]
17. Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease.
Dukinfield M; Maniati E; Reynolds LE; Aubdool A; Baliga RS; D'Amico G; Maiques O; Wang J; Bedi KC; Margulies KB; Sanz-Moreno V; Hobbs A; Hodivala-Dilke K
J Pathol; 2019 Dec; 249(4):523-535. PubMed ID: 31424556
[TBL] [Abstract][Full Text] [Related]
18. Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy.
Papait R; Serio S; Pagiatakis C; Rusconi F; Carullo P; Mazzola M; Salvarani N; Miragoli M; Condorelli G
Circulation; 2017 Sep; 136(13):1233-1246. PubMed ID: 28778944
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.
Li Q; Xie J; Wang B; Li R; Bai J; Ding L; Gu R; Wang L; Xu B
PLoS One; 2016; 11(2):e0148480. PubMed ID: 26914935
[TBL] [Abstract][Full Text] [Related]
20. Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex.
Funamoto M; Sunagawa Y; Gempei M; Shimizu K; Katanasaka Y; Shimizu S; Hamabe-Horiike T; Appendino G; Minassi A; Koeberle A; Komiyama M; Mori K; Hasegawa K; Morimoto T
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
